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Abstract
Cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) is a master 
anti-apoptotic regulator and resistance factor that suppresses tumor necrosis factor-α (TNF-α), 
Fas-L, and TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, as well as 
apoptosis triggered by chemotherapy agents in malignant cells. c-FLIP is expressed as long (c-
FLIPL), short (c-FLIPS), and c-FLIPR splice variants in human cells. c-FLIP binds to FADD 
and/or caspase-8 or -10 and TRAIL receptor 5 (DR5) in a ligand-dependent and -independent 
fashion and forms an apoptosis inhibitory complex (AIC). This interaction in turn prevents death-
inducing signaling complex (DISC) formation and subsequent activation of the caspase cascade. c-
FLIPL and c-FLIPS are also known to have multifunctional roles in various signaling pathways, as 
well as activating and/or upregulating several cytoprotective and pro-survival signaling proteins 
including Akt, ERK, and NF-kB. Upregulation of c-FLIP has been found in various tumor types, 
and its silencing has been shown to restore apoptosis triggered by cytokines and various 
chemotherapeutic agents. Hence, c-FLIP is an important target for cancer therapy. For example, 
small interfering RNAs (siRNAs) that specifically knockdown the expression of c-FLIPL in 
diverse human cancer cell lines augmented TRAIL-induced DISC recruitment and increased the 
efficacy of chemotherapeutic agents, thereby enhancing effector caspase stimulation and 
apoptosis. Moreover, small molecules causing degradation of c-FLIP as well as decreasing mRNA 
and protein levels of c-FLIPL and c-FLIPS splice variants have been found, and much effort is 
focused on developing other c-FLIP-targeted cancer therapies. This review focuses on (1) the anti-
apoptotic role of c-FLIP splice variants in preventing apoptosis and inducing cytokine and 
chemotherapy drug resistance, (2) the molecular mechanisms and factors that regulate c-FLIP 
expression, and (3) modulation of c-FLIP expression and function to eliminate cancer cells or 
increase the efficacy of anticancer agents. This article is part of a Special Issue entitled 
“Apoptosis: Four Decades Later”.
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INTRODUCTION
The FADD-like interleukin-1β–converting enzyme (FLICE)-inhibitory (c-FLIP) proteins 
negatively regulate the signaling complex downstream of death receptors. In this review, I 
discuss (1) apoptosis signaling pathways and the role of c-FLIP isoforms as critical anti-
apoptotic and drug resistance factors, (2) assess the potential for improving the outcome of 
cancer therapy by targeting c-FLIP and exploring the possibility of increasing its 
degradation and/or decreasing its expression to provide a safer approach to treat cancer, and 
(3) discuss novel c-FLIP targeted agents for cancer therapy that improve the efficacy of 
TRAIL and cytotoxic drugs.
APOPTOSIS SIGNALING PATHWAYS
Apoptosis is the orderly and tightly regulated cellular programmed cell death involving 
signal transduction pathways that induce cells to self-destruct during embryonic 
development, or in response to environmental hazards (e.g., radiation-induced DNA 
damage) or anticancer therapeutics. Apoptosis pathways provide control against cancer 
development, but specific mutations enable malignant cells to escape apoptosis and lead to 
tumor formation. Two major well-studied pathways, the intrinsic or mitochondrion-initiated 
pathway and the extrinsic or cell surface death receptors pathway, are involved in apoptosis 
(Fig. 1) [1–3]. In the mitochondrial pathway, cytochrome c, certain caspases, apoptosis-
inducing factor, Smac/DIABLO, and other apoptosis-inducing factors are released from the 
mitochondrial intramembrane space to the cytosol [4]. Once released, cytochrome c and 
dATP bind to apoptotic proteinase-activating factor-1 (Apaf-1), and this complex along with 
adenine nucleotides promote procaspase-9 autoactivation [5], which in turn activates 
caspases-2, -3, -6, -7, -8, and -10. Apoptosis triggered by various stimuli requires direct 
activation of Bax and BAK at the mitochondria by a member of the Bcl-2 homology 
domain-3 (BH3)-only family of proteins including Bid, Bim, or PUMA [6]. The various 
anti- and pro-apoptotic members of the Bcl-2 family form an interactive network that finally 
regulates the release of apoptosis triggering factors such as cytochrome c to the cytoplasm 
[7]. Apoptosis initiated by the endoplasmic reticulum (ER) stress signaling pathway is also 
mainly dependent on the release of cytochrome c into the cytosol [8]. This release is 
associated with opening the permeability transition pore (PTP) and a collapse of 
mitochondrial transmembrane potential (ΔΨm) due to the intake of Ca2+ following its release 
into the cytosol from the ER. Certain members of the Bcl-2 family on the ER appear to have 
a comprehensive function in the maintenance of ER homeostasis, participation in ER stress 
signal transduction pathways, and apoptosis [8].
In the extrinsic or death receptor-mediated apoptosis pathway (e.g., Fas/Fas ligand 
interaction, tumor necrosis factor-α [(TNF-α)/TNF receptor 1 (TNFR1), or TRAIL/DR5 
interaction and cell death], the initiator caspases-8 and -10 activate the downstream caspases 
including caspase-3 [9–11]. Active caspases-8 and -10 are known to cleave a pro-apoptotic 
Bcl-2 family member, Bid, and the truncated Bid induces mitochondrial cytochrome c 
release [26–29], thereby linking the two pathways. After activation, both caspases-8 and -9 
activate caspase-3, which in turn cleaves other caspases and many cellular proteins [2, 12–
14]. Another pathway related to the intrinsic apoptotic pathway has also been identified [15]. 
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In this pathway, BID is cleaved in response to several death-inducing stimuli (staurosporine, 
UV radiation, cycloheximide, etoposide) and this BID cleavage is blocked by Bcl-2, 
suggesting that degradation of BID occurred distal to cytochrome c release. Moreover, 
addition of cytochrome c to Jurkat post-nuclear extracts triggered cleavage of BID at Asp-59 
which was catalyzed by caspase-3 rather than caspase-8. These results provide evidence that 
caspase-3 mediated cleavage of BID represents a feedback loop for the amplification of 
mitochondrial cytochrome c release during cytotoxic drug- and UV radiation-induced 
apoptosis [15].
CELLULAR FLICE-LIKE INHIBITORY PROTEIN (C-FLIP)
Structure of c-FLIP
The anti-apoptotic protein c-FLIP is a death effector domain (DED)-containing protein that 
is recruited to the DISC and regulates activation of caspases-8 and -10 in the death receptor 
signaling pathways (Fig. 1). c-FLIP has 13 distinct spliced variants, three of which are 
expressed as proteins: the 26 kDa short form (c-FLIPS), the 24 kDa form of c-FLIP (c-
FLIPR), and the 55 kDa long form (c-FLIPL) [16–18] (Fig. 2). The structures of c-FLIPS and 
the viral v-FLIP proteins are similar, except that the two DEDs of c-FLIPS are followed by 
20 amino acids that appear to be crucial for its ubiquitaation and targeting for proteasomal 
degradation [11, 16–18]. c-FLIPR also contains two DEDs but lacks the additional carboxy 
(C)-terminal amino acids that are present in c-FLIPS. The C-terminus of c-FLIPL is longer 
than that of c-FLIPS and closely resembles the structure of caspases-8 and -10 [11, 16–18], 
but this region of c-FLIPL does not contain a functional caspase domain. This lack of 
caspase activity is the result of several amino acid substitutions, particularly the crucial 
cysteine residue in the catalytic domain which is necessary for the catalytic activity of 
caspases [11, 16]. Additionally, c-FLIPL has a caspase-8 cleavage site at position Asp-376 
(LEVD); c-FLIPL cleavage at this site produces the proteolytic fragment variant p43c-FLIP 
[11, 16–18]. The C-terminal region of c-FLIPS and c-FLIPR play a crucial role in 
ubiquitnation and degradation as well as the anti-apoptotic function of these isoforms [11, 
16–18]. In humans, the decision to make c-FLIPS or c-FLIPR is defined by a single 
nucleotide polymorphism in a 3′ splice site of the c-FLIP gene. An intact splice site directs 
production of c-FLIPS, but the splice-dead variant causes production of c-FLIPR [19]. 
Because of differences in protein translation rates, higher levels of c-FLIPS protein are 
produced compared with c-FLIPR [19]. The three c-FLIP variants can interact with the 
adaptor protein FADD.
c-FLIP transcription and translation
c-FLIP can be transcriptionally activated by various stimuli. These include TNF ligands, 
growth factors, interleukins, chemokines, and chemotherapeutic agents [11]. Several 
transcription factors are known to transcriptionally regulate the c-FLIP gene [11, 18]. These 
include NF-κB, p53 tumor suppressor protein, p63, E2F1, c-myc, IRF5, c-Fos, nuclear 
factor of activated T cells (NFAT), heterogeneous nuclear ribonucleo-protein K (hnRNP K), 
the forkhead transcription factor FOXO3a, early growth response-1 transcription factor 
(EGR1), androgen receptor (AR), E2F1, AP-1, and SP1. While NF-κB, p63, NFATc2, 
EGR1, hnRNP K, AR and SP1 induce c-FLIP, c-myc, FOXO3a, c-Fos, IRF5, and SP3 
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suppress c-FLIP transcription [11, 18]. p53 may transcriptionally upregulate the c-FLIP gene 
and also promote the degradation of c-FLIP protein [16]. Moreover, Gli2 transcription factor 
upregulates c-FLIPS and c-FLIPL [20]. c-FLIPS is highly induced upon activation of T cells, 
primarily via the calcineurin-NFAT pathway [16]. The human T-cell leukemia virus type 1 
(HTLV-1) Tax protein upregulates c-FLIP in HTLV-1-infected cells through activation of 
NF-κB [6]. c-FLIPS is also upregulated at the translational level and causes TRAIL 
resistance in glioblastoma multiforme (GBM) cells due to activation of the Akt mammalian 
target of rapamycin (mTOR)-p70 S6 kinase 1 (S6K1) pathway [21, 22]. Conversely, 
inhibition of mTOR or its target S6K1 suppressed polyribosomal accumulation of c-FLIPS 
mRNA, c-FLIPS protein expression, and promoted TRAIL resistance in GBM cells. 
Moreover, it has been shown that Rocaglamide (Roc) sensitizes resistant adult T-cell 
leukemia/lymphoma (ATL) cells to DR4- and DR5-mediated apoptosis by translational 
suppression of c-FLIPS through inactivation of the translation initiation factor 4E (eIF4E) 
[16, 23].
c-FLIP degradation
Both c-FLIPL and c-FLIPS isoforms are short-lived proteins that are predominately degraded 
by the ubiquitin-proteasome degradation system [11, 16, 18]. Both c-FLIP isoforms can be 
degraded by the proteasome. However, c-FLIPS is particularly sensitive to ubiquitination and 
proteasomal degradation, partly due to two crucial lysine residues in the C-terminal 20 
amino acids that are unique to c-FLIPS [24]. The sensitivity of c-FLIPS to ubiquitin-
mediated degradation adds a novel concept to DISC regulation and its control of apoptosis 
[24]. c-FLIPL and c-FLIPS levels are also regulated by JNK activation via the E3 ubiquitin 
ligase Itch [11, 18, 25]. Phosphorylation events also play important roles in the regulation of 
c-FLIP protein levels. For instance, protein kinase C (PKC) phosphorylation at the serine 
193 (S193) residue of c-FLIPS inhibits its polyubiquitination, stabilizes c-FLIPS levels, and 
increases cell survival [66]. S193 phosphorylation is markedly increased by treatment with 
the PKC activator 12-O-tetradecanoylphorbol-13-acetate and decreased by inhibition of 
PKCα and PKCβ. Phosphorylation of the S193 residue also decreased the ubiquitination of 
c-FLIPL but did not affect its stability, indicating that S193 phosphorylation has a different 
function in c-FLIPL than in c-FLIPS. Moreover, pretreatment with the PKCδ-selective 
inhibitor rottlerin or transfection with PKCδ siRNA inhibited phorbol myristate acetate 
(PMA)-induced c-FLIP expression, which identifies a role for PKCδ in c-FLIP induction 
[26].
Upregulation of c-FLIP in human cancers
Increased expression of c-FLIP isoforms has been shown in cell lines from various types of 
cancer including colorectal [11, 16, 18]. Elevated levels of c-FLIP in tumor tissue from 
patients with colorectal cancer [28, 29], bladder urothelial cancer [30], cervical cancer [31], 
Burkitt’s lymphoma [32], non-Hodgkin’s lymphoma [33], head and neck squamous cell 
carcinoma (HNSCC) [34], and hepatocellular cancers [35] have been correlated with a poor 
clinical outcome and could be a reliable prognostic factor in these types of cancer. c-FLIP 
upregulation is also seen in gastric cancer and plays an important role in lymph node 
metastasis, which ultimately contributes to tumor progression [36]. c-FLIP isoforms are also 
expressed in pancreatic intraepithelial neoplasms as well as pancreatic ductal 
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adenocarcinomas, whereas normal pancreatic ducts were consistently negative for c-FLIP 
expression [37]. McCourt et al. [38] reported that c-FLIP expression was increased in high-
grade prostatic intraepithelial neoplasia (HGPIN) and prostate cancer tissue relative to 
normal prostate epithelium. Significantly, these authors found that maximal c-FLIP 
expression was detected in castrate-resistant prostate cancer (CRPC).
C-FLIP FUNCTION
c-FLIP prevents apoptosis
Initial studies with animal models have revealed that c-FLIP plays an important role in T-cell 
proliferation and heart development [39, 40]. Moreover, abnormal c-FLIP expression has 
been found in various diseases such as cancer, multiple sclerosis, Alzheimer’s disease, 
diabetes mellitus, and rheumatoid arthritis [11, 17]. c-FLIP is also thought to be the main 
causal factor of “immune escape” [41]. c-FLIP is involved in TRAIL, Fas, TNF-α, and 
chemotherapeutic drug resistance in a wide range of human malignancies [11, 16–18]. 
Moreover, studies using c-FLIP-deficient mice support a dual function for c-FLIPL by 
confirming a role for c-FLIP in Fas L, TNF-α-induced apoptosis and revealing that c-FLIP 
has a similar function to caspase-8 in heart development [40]. Nevertheless, extensive 
literature encompassing diverse types of human cancer cells now indicates that the action of 
c-FLIP is generally anti-apoptotic in cancer cells. Furthermore, interference with c-FLIP 
expression sensitizes tumor cells to death ligands and chemotherapy in experimental models 
[11, 18, 42–45]. In addition to its function as an apoptosis modulator, c-FLIP exerts other 
cellular functions including increased cell proliferation and tumorigenesis [11, 17–19].
The structural differences between human c-FLIP variants indicate distinct regulatory roles 
for c-FLIPL and c-FLIPS in apoptosis. c-FLIPS inhibits TRAIL-induced DISC formation and 
apoptosis [24, 45], while c-FLIPL is responsible for the dual functions described above 
whereby it inhibits Fas-induced caspase-8 activation when expressed at high levels, but 
enhances caspase-8 activation when its expression level is low [11, 18]. c-FLIPS also 
suppresses apoptosis by inhibiting caspase-8 activation [46, 47]. Moreover, c-FLIPS inhibits 
oxaliplatin-induced apoptosis through the sustained XIAP protein level and Akt activation 
[48].
We have demonstrated that c-FLIPL interacts with DR5, FADD, and caspase-8 forming an 
apoptotic inhibitory complex (AIC) in MCF-7 breast cancer cells [49]. Moreover, silencing 
the c-FLIP gene by a specific siRNA leads to (1) death ligand-independent but DR5-, 
FADD-, and caspase-8- and -9-dependent apoptosis in these cells, and (2) the knockdown of 
c-FLIP expression inhibits breast cancer cell proliferation and triggers spontaneous 
apoptosis by activating both the death receptor and mitochondrial pathways [49]. Our data 
support the previous report by Jin et al. [50] demonstrating that the peptide corresponding to 
the DR5 binding domain of c-FLIPL induces apoptosis in cancer cells. It is possible that 
inhibiting the interaction of DR5 and c-FLIPL by peptides or small molecule inhibitors could 
provide a mechanism by which tumor-selective apoptosis can be achieved.
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c-FLIP activates cytoprotective pathways
As shown in Fig. 3, c-FLIP activates several cytoprotective signaling pathways involved in 
regulating cell survival, proliferation, and carcinogenesis. Overexpression of c-FLIPL 
activates NF-κB and ERK signaling by binding to adaptor proteins in each pathway, such as 
TNFR-associated factors 1 (TRAF1) and 2 (TRAF2), receptor-interacting protein 1 (RIP), 
and Raf-1 [19, 51] (see Fig. 3). The caspase-8 processed N-terminal fragment of c-FLIPL 
(p43cFLIP) is more efficient than c-FLIPL at recruiting TRAF2 and RIP1, leading to more 
robust NF-κB activation [19, 20, 52, 53]. Golks et al. [54] found that in nonapoptotic cells, 
c-FLIP and the procaspase-8 heterodimer result in a novel NH2-terminal fragment of c-FLIP 
(p22-FLIP) which is the key mediator of NF-κB activation by binding to the IKK complex. 
Moreover, TNF-α-mediated JNK activation increases turnover of NF-κB-induced c-FLIP 
[25]. This is not the result of direct c-FLIP phosphorylation, but rather depends on JNK-
mediated phosphorylation and activation of the E3 ubiquitin ligase Itch which specifically 
ubiquitinates c-FLIP and induces its proteasomal degradation. Thus, JNK antagonizes NF-
κB during TNF-α signaling by promoting the proteasomal elimination of c-FLIPL [25].
Akt, a serine-threonine kinase, interacts with c-FLIPL protein and c-FLIPL enhances the 
anti-apoptotic functions of Akt [55, 56] by modulating Gsk3β activity. Moreover, through its 
effects on Gsk3β, c-FLIPL overexpression in cancer cells induces resistance to TRAIL. This 
effect is mediated by regulation of p27 (Kip1) and caspase-3 expression [56]. Down-
regulation of the DNA-PK/Akt pathway is also reported to correlate with high 
responsiveness to TRAIL-mediated growth inhibition and apoptosis [57]. siRNA-mediated 
suppression of DNA-PK or treatment with 4,5-dimethoxy-2-nitrobenzaldehyde (DMNB), an 
inhibitor of DNA-PK, led to decreased phosphorylation of Akt and Bad (a target molecule of 
Akt), increased expression of DR4/DR5, and downregulation of c-FLIP [57]. Therefore, 
inhibition of the DNA-PK/Akt pathway may be clinically useful in treating TRAIL-resistant 
cancer cells [58].
Panner et al. [59] demonstrated that a novel phosphatase and tensin homologue (PTEN)-Akt-
atrophin-interacting protein 4 (AIP4) pathway regulates c-FLIPS ubiquitination and stability 
in GBM cell lines and xenografts. However, how PTEN and Akt are linked to AIP4 activity 
was unclear. These authors described a second regulator of ubiquitin metabolism, the 
ubiquitin-specific protease 8 (USP8), which is a downstream target of Akt, and how it links 
Akt to AIP4 and the regulation of c-FLIPS stability [60]. Overexpression of USP8 increased 
c-FLIPS ubiquitination, decreased c-FLIPS half-life, decreased c-FLIPS steady-state levels, 
and decreased TRAIL resistance. Therefore, PTEN appears to use control of ubiquitination 
to regulate TRAIL sensitivity in GBM cells.
c-FLIPL also interacts with the death domain-associated protein Daxx and prevents Fas-
induced JNK activation [61]. Thus, c-FLIPL acting on both the FADD- and Daxx-mediated 
signaling pathways may be involved in inhibiting Fas-induced cell death. Furthermore, c-
FLIPL directly interacts with a JNK activator, MAP kinase kinase 7 (MKK7), in a TNF-α-
dependent manner and inhibits the interactions of MKK7 with MAP/ERK kinase kinase 1 
(MEKK1), apoptosis signal-regulating kinase 1, (ASK1) and TGF-β-activated kinase 1. This 
interaction of c-FLIPL with MKK7 might selectively suppress JNK activation [62] (see Fig. 
3).
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Another regulator of c-FLIP upregulation is calcium/calmodulin-dependent protein kinase II 
(CaMK II), which protects cancer cells from TRAIL-induced apoptosis. Treating resistant 
cells with the CaMK II inhibitor KN-93 inhibited CaMK II activity, reduced c-FLIP 
expression, inhibited c-FLIP phosphorylation, and rescued Fas agonistic antibody (CH-11) 
sensitivity [63, 64]. Phosphorylation of c-FLIP variants by CaMK II appears to promote c-
FLIPL recruitment to the DISC and inhibit TRAIL-induced apoptosis [63, 64], but 
phosphorylation of c-FLIPL by PKC or the bile acid glycochenodeoxycholate results in 
decreased c-FLIPL recruitment to the DISC [65]. Thus, the particular site of phosphorylation 
on c-FLIPL appears to influence the functional effect of this protein on apoptosis. It has been 
shown that calmodulin (CaM) binds directly to c-FLIPL in a calcium-dependent manner and 
prevents Fas-triggered apoptosis [66]. Interestingly, a point mutation at H204 of c-FLIPL 
markedly decreases CaM binding [67]. Therefore, inhibition of CaM/c-FLIP interaction may 
provide a new therapeutic strategy for cancer treatment.
Overexpression of c-FLIP can alter cell cycle progression and enhance cell proliferation and 
carcinogenesis [68, 69]. Increased expression of c-FLIPL inhibited the ubiquitination and 
proteasomal degradation of β-catenin, resulting in an increase in the target gene cyclin D1, 
colony formation, and invasive activity in prostate cancer cells. The c-FLIP/β-catenin/cyclin 
D1 signals contributing to colony formation and invasion were reversed by selective 
silencing of c-FLIP expression [70]. Similarly, c-FLIPL, in cooperation with FADD, 
enhances canonical Wnt signaling by inhibiting proteasomal degradation of β-catenin, thus 
suggesting an additional mechanism of tumorigenesis [70]. Moreover, a role for nuclear c-
FLIPL in modulating Wnt signaling has been established [71]. Interestingly, a deficiency of 
the adenomatous polyposis coli (APC) gene and subsequent activation of β-catenin can also 
lead to repression of c-FLIP expression through activation of c-Myc [72], c-FLIP 
upregulation may contribute to the carcinogenesis and aggressiveness of endometrial 
carcinomas and serve as a useful prognostic factor for this tumor [71, 73]. c-FLIP 
overexpression is also significantly related to the presence of high-risk human 
papillomavirus (HR-HPV) infection during the progression of cervical squamous cell cancer, 
and c-FLIP is an early marker of cervical carcinogenesis [74]. Moreover, HPV16 E2 protein 
interacts with and abrogates the apoptosis inhibitory function of c-FLIP and renders cervical 
cancer cell lines hypersensitive to Fas/FasL apoptosis. This observation may be useful for 
developing therapeutic strategies to silence c-FLIP for intervention with cervical 
carcinogenesis [75]. Overexpression of c-FLIPL also increases hypoxia-inducible factor-1α 
(HIF1α) [76]. In turn, overexpression of HIF1α can result in regulation of genes responsible 
in cell proliferation, metastasis, and invasion. Moreover, c-FLIP overexpression accelerated 
progression to androgen independence by inhibiting apoptosis in LNCaP prostate tumors 
implanted in nude mice [77].
Much evidence has clearly demonstrated that c-FLIPS plays a major role in causing 
resistance to death ligands and chemotherapeutic agents. Park et al. [78] reported that 
MEK1/2 inhibitors synergistically interact with the heat shock protein 90 (HSP90) inhibitor 
and geldanamycins [17-allylamino-17-demethoxygeldanamycin (17AAG) and 17-
dimethylaminoethylamino-17-demethoxygeldanamycin] to kill hepatoma and pancreatic 
carcinoma cells. Treating cells with MEK1/2 inhibitors and 17AAG reduced expression of c-
FLIPS that was connected to loss of MEK1/2 and AKT function. Moreover, overexpression 
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of c-FLIPS or inhibition of caspase-8 abolished cell killing by MEK1/2 inhibitors and 
17AAG. Interestingly, Panner et al. [79] reported that HSP90α recruits c-FLIPS to the DISC 
and contributes to TRAIL resistance. Furthermore, combinations of sorafenib and vorinostat 
increased CD95 surface levels and CD95 association with caspase-8, and knockdown of 
CD95 or FADD expression reduced sorafenib/vorinostat-induced cell death [80]. Signaling 
by CD95 caused protein kinase R (PKR)-like endoplasmatic reticulum kinase (PERK) 
activation that was responsible for both promoting caspase-8 association with CD95 and 
increased eIF2α phosphorylation. Suppression of eIF2α function abolished sorafenib/
vorinostat lethality. Cell death was paralleled by PERK- and eIF2α-dependent reduction of 
c-FLIPs protein levels, while overexpression of c-FLIPS maintained cell viability [80]. 
Similarly, expression of phosphorylation-insensitive eIF2α-S51A blocked sorafenib- and 
vorinostat-induced suppression of c-FLIPS levels and overexpression of c-FLIPS [81]. 
Overexpression of c-FLIPS also suppressed cell death by the multinuclear platinum 
chemotherapeutic BBR3610 [82].
c-FLIP as a therapeutic target for cancer treatment
c-FLIP can serve as a critical target for therapeutic intervention aimed at inhibiting its 
transcription and posttranscriptional changes [11, 16]. Ectopic expression of c-FLIP variants 
decreases apoptosis caused by death ligands and anticancer agents [24], indicating that 
overexpression of these proteins may cause resistance to multiple anticancer drugs. It does 
not appear possible to inhibit c-FLIP function with small molecule ligands since c-FLIP has 
significant structural similarity to caspase-8 (Fig. 2). This resemblance to caspase-8 makes 
c-FLIP protein a very difficult target for drugs to inhibit its function, since small molecules 
capable of blocking its recruitment to the DISC would also likely inhibit recruitment of 
caspase-8, thereby inhibiting apoptosis. Therefore, to reduce or inhibit c-FLIP expression, 
small molecules which target c-FLIP without inhibiting caspases-8 and -10 are needed. 
Several review articles have discussed classes of agents that decrease c-FLIP expression and 
sensitize cancer cells to TRAIL or anticancer drugs [11, 16, 18, 83]. These agents affect c-
FLIP transcription, trigger c-FLIP degradation through the ubiquitin-proteasome system, or 
decrease c-FLIP translation. Moreover, DNA damaging agents are promising drugs with 
regard to downregulating levels of c-FLIP variants. Pretreatment with chemotherapeutic 
drugs including cisplatin, doxorubicin, or topoisomerase I inhibitors (camptothecin, 9-NC, 
irinotecan) downregulates c-FLIP variants expression in various tumor cells by inhibiting its 
transcription and rendering cells sensitive to death receptor-triggered apoptosis [84–90].
Several histone deacetylase inhibitors (HDACi) have been shown to significantly 
downregulate c-FLIP expression in various cancer cells at the transcriptional and 
translational levels [11, 91–94]. Among these, suberoylanilide hydroxamic acid (SAHA, 
vorinostat) is the most promising HDACi that causes robust inhibition of c-FLIP variants 
[91]. TRAIL-triggered apoptosis in breast cancer cells was blocked at the level of apical 
activation of caspase-8, and SAHA enhanced the TRAIL-induced processing and activation 
of procaspase-8. Interestingly, degradation of c-FLIPL and c-FLIPS by a ubiquitin/
proteasome-dependent Itch/AIP4-independent mechanism is observed upon exposure to 
SAHA [91]. We recently showed that a new HDACi, 4-(4-chloro-2-methylphenoxy)-N-
hydroxybutanamide (CMH) [93] or droxinostat [94], identified using a high-throughput 
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chemical library screen [95, 96], triggered apoptosis in the breast cancer cell line MCF-7 
through c-FLIPL and c-FLIPS mRNA as well as protein downregulation [93]. Interestingly, 
this agent induced more robust apoptosis in a doxorubicin-resistant variant of MCF-7 cells 
[93]. Among c-FLIP inhibitors, histone deacetylase inhibitors have been very effective 
agents. Particularly significant is the recent discovery by Kerr et al. [97] reporting a novel 
interaction between c-FLIP and Ku70, a key component of non-homologous end joining 
machinery in the DNA damage pathway in the HCT-116 human colon cancer cell line. 
Interestingly, Ku70 regulates c-FLIP protein stability by inhibiting its polyubiquitination 
[97]. Moreover, these authors showed that vorinostat (SAHA) increased the acetylation of 
Ku70, thereby disrupting the c-FLIP/Ku70 complex and initiating c-FLIP polyubiquitination 
and degradation by the proteasome. Furthermore, the HDAC6-specific inhibitor Tubacin 
mimicked the effects of SAHA, suggesting that HDAC6 is a critical regulator of Ku70 
acetylation and c-FLIP protein stability [97].
Small molecule therapeutics that selectively down-regulate c-FLIPS or c-FLIPL and gene 
therapy strategies that knock down a specific c-FLIP variant have been used to downregulate 
these variants. Developing these innovative therapeutic strategies in conjunction with TRAIL 
and chemotherapeutic agents could potentially overcome the barrier of dose-limiting toxicity 
in cancer chemotherapy. TRAIL or chemotherapy resistance in diverse cancer cell types can 
be reversed by parallel treatment with agents known to downregulate c-FLIP variants.
CONCLUSIONS
Accumulating evidence shows that c-FLIP variants induce resistance to death receptor 
ligands and chemotherapeutic agents in various cancer cells. Moreover, c-FLIP upregulation 
correlates with a poor clinical outcome and could be a reliable prognostic factor in several 
types of cancer. Therefore, c-FLIP isoforms may be a relevant clinical target for 
counteracting therapy-resistant human malignancies. Various classes of agents can 
downregulate c-FLIP expression. Since c-FLIP has significant structural similarity to 
caspase-8, it is very difficult to target c-FLIP directly since small molecules capable of 
blocking the recruitment of c-FLIP to the DISC could simultaneously inhibit the recruitment 
of caspase-8 and thereby inhibit apoptosis. Therefore, to reduce or inhibit c-FLIP 
expression, small molecules which target c-FLIP without inhibiting caspases-8 and -10 are 
needed. Compounds that inhibit or downregulate c-FLIP mRNA expression or cause 
degradation of c-FLIP at the protein level through proteasome degradation will be of 
particular interest.
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Fig. 1. 
Apoptosis pathways and roles of c-FLIP in preventing apoptosis. TRAIL interaction with 
DR4 and DR5 transduces the death receptor (extrinsic) and mithochondrial apoptosis 
signaling pathways through activation of caspases-8 and -10 (see the text for detailed 
information). c-FLIP isoforms are major anti-apoptotic proteins that suppress caspase-8 and 
-10 activation, and therefore prevent the downstream apoptosis cascade
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Fig. 2. 
Structures of c-FLIP variants. Three c-FLIP variants, c-FLIPL, c-FLIPS, and c-FLIPR, 
contain two death effector domains (DEDs) at their N termini. In addition to two DEDs, c-
FLIPL contains a large (p20) and a small (p12) caspase-like domain without catalytic 
activity. c-FLIPS and c-FLIPR consist of two DEDs and a small C terminus. Depending on 
its cellular level at the DISC, c-FLIPL may act as an anti-apoptotic or pro-apoptotic factor 
[9, 16, 18]. c-FLIPS, c-FLIPS, c-FLIPR, and two cleavage products of c-FLIP (p43-FLIP and 
p22-FLIP) act as anti-apoptotic proteins [9, 16, 18]. p43-FLIP and p22-FLIP are generated 
from c-FLIPL by procaspase-8 cleavage at D376 [9] (adapted from [9, 16, 18])
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Fig. 3. 
Multifunctional roles of c-FLIP on various signaling pathways. As discussed in the text, in 
addition to its functional role in inhibiting apoptosis by binding to procaspases-8 and -10 
and inhibiting their activation, c-FLIP activates various anti-apoptotic and cell survival 
signaling pathways, leading to proliferation and cell survival
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